Optimizing dosage and duration therapy for chronic hepatitis C «difficult-to-treat patients»

Journal Title: Annals of Hepatology - Year 2008, Vol 7, Issue 4

Abstract

Authors and Affiliations

José Ladero

Keywords

Related Articles

NASH and cryptogenic cirrhosis: A histological analysis†

Introduction. Epidemiological studies indicate that nonalcoholic steatohepatitis (NASH) is a common cause of cirrhosis described as ‘cryptogenic’. To address this from a histological perspective and to examine the signif...

Hepatopulmonary syndrome - Past to present

Hepatopulmonary syndrome (HPS) is the one of the complication of liver cirrhosis with portal hypertension, irrespective of etiology, age and sex. It has also been observed in non cirrhotic portal hypertension and in acut...

Utility and safety of tolvaptan in cirrhotic patients with hyponatremia: A prospective cohort study

[sup][/sup] Introduction and aim. Hyponatremia is common in patients with decompensated cirrhosis and is associated with increased mortality. Tolvaptan, a vasopressor V2 receptor antagonist, can increase free water excre...

Autoimmune hepatitis with giant-cell transformation

Background/Aims: Giant-cell hepatitis (GCH), also known as postinfantile or syncytial giant cell hepatitis, is a frequent pattern of liver injury in the neonate, primarily seen in the first three months of life. Few case...

Download PDF file
  • EP ID EP77818
  • DOI -
  • Views 138
  • Downloads 0

How To Cite

José Ladero (2008). Optimizing dosage and duration therapy for chronic hepatitis C «difficult-to-treat patients». Annals of Hepatology, 7(4), 392-394. https://europub.co.uk./articles/-A-77818